United Asset Strategies Inc. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 12.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,736 shares of the company’s stock after selling 643 shares during the period. United Asset Strategies Inc.’s holdings in Johnson & Johnson were worth $613,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the business. Zions Bancorporation N.A. raised its holdings in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock worth $2,810,000 after purchasing an additional 73 shares in the last quarter. Portland Global Advisors LLC raised its holdings in shares of Johnson & Johnson by 0.9% in the 3rd quarter. Portland Global Advisors LLC now owns 8,744 shares of the company’s stock worth $1,131,000 after purchasing an additional 78 shares in the last quarter. Vishria Bird Financial Group LLC raised its holdings in shares of Johnson & Johnson by 3.0% in the 2nd quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock worth $381,000 after purchasing an additional 80 shares in the last quarter. Alta Capital Management LLC raised its holdings in shares of Johnson & Johnson by 3.9% in the 3rd quarter. Alta Capital Management LLC now owns 2,184 shares of the company’s stock worth $282,000 after purchasing an additional 82 shares in the last quarter. Finally, G&S Capital LLC raised its holdings in shares of Johnson & Johnson by 1.8% in the 3rd quarter. G&S Capital LLC now owns 4,668 shares of the company’s stock worth $604,000 after purchasing an additional 84 shares in the last quarter. 72.25% of the stock is owned by hedge funds and other institutional investors.
JNJ stock traded up $1.57 during trading hours on Friday, hitting $133.00. The company’s stock had a trading volume of 4,856,974 shares, compared to its average volume of 7,224,392. The company has a quick ratio of 1.00, a current ratio of 1.26 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $343.25 billion, a PE ratio of 16.26, a price-to-earnings-growth ratio of 2.20 and a beta of 0.69. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99. The stock has a 50 day moving average price of $130.83 and a two-hundred day moving average price of $134.05.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.12. The company had revenue of $20.73 billion during the quarter, compared to the consensus estimate of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.05 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 8.65 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 2.86%. The ex-dividend date of this dividend is Monday, November 25th. Johnson & Johnson’s dividend payout ratio is 46.45%.
A number of research firms recently commented on JNJ. Sanford C. Bernstein upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 target price on the stock in a report on Friday, October 11th. Wells Fargo & Co dropped their target price on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a report on Wednesday, October 16th. Goldman Sachs Group set a $169.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Tuesday, August 27th. Bank of America restated a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a report on Tuesday, July 16th. Finally, Credit Suisse Group boosted their target price on shares of Johnson & Johnson from $158.00 to $163.00 in a research report on Thursday, October 24th. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $151.64.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: What is diluted earnings per share (Diluted EPS)?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.